

### Corporate Profile

Luminex® Corporation (NASDAQ: LMNX) develops, manufactures and markets proprietary biological testing technologies, with applications throughout the life-sciences industry. This industry depends on a broad range of tests, known as "bioassays," to discover new drugs, identify new genes or simply monitor blood cholesterol levels. The in-house experts at Luminex have developed an innovative approach to bioassays, known as xMAP® technology. This groundbreaking technology enables companies and laboratories to perform bioassays more quickly and cost-effectively than with other systems, without sacrificing accuracy.

Luminex has been marketing the current generation of xMAP technology (formerly known as LabMAP®) worldwide since 1999. Thanks to its open-architecture platform, xMAP technology can be applied across a wide range of markets. In fact, xMAP technology-based systems are already in use by leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.

Escalating research and development spending, along with the evolution of pharmacogenomics, are fueling the growth of the drug discovery, clinical diagnostics and biomedical research markets - including both genomics and proteomics research. With this expansion of market opportunities, Luminex is strategically positioned for sustained growth and success.

### Stock Performance

LMNX (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$20.56
Change (%)	▼ 0.08 (0.39%)
Volume	174,639
52 Week Low	\$17.68
Market Cap	\$905,759,965
Rolling EPS	0.67
PE Ratio	30.7408
Shares Outstanding	44,054,473

Data as of 01/19/18 4:00 p.m. ET



### Recent Headlines

- 01/07/18 - 4:00 p.m.  
Luminex Announces Preliminary Revenue for the Fourth Quarter and Full Year 2017; Company to Present at 36th Annual J.P. Morgan Healthcare Conference
- 12/13/17 - 4:05 p.m.  
Luminex Corporation Declares Fourth Quarter Cash Dividend

### Upcoming Events

Date	Title
11/29/17 8:00 a.m. ET	Luminex Corp at Piper Jaffray Healthcare Conference

### Primary IR Contact

Matthew Scalo  
Senior Director, Investor Relations  
**Phone:** 512.336.3587  
**E-mail:** mscalo@luminexcorp.com

11/14/17 - 4:06 p.m.  
Luminex Corporation To Present At The 29th Annual Piper Jaffray  
Healthcare Conference

01/11/18 10:00  
a.m. PT Luminex Corp at 36th Annual J.P. Morgan  
Healthcare Conference

### Corporate Governance

Nachum "Homi" Shamir	President and Chief Executive Officer
Harriss T. Currie	Chief Financial Officer, Senior Vice President, Finance and Treasurer
Nancy M. Fairchild, SPHR	Senior Vice President, Human Resources
Randall "Randy" Myers	Senior Vice President, Global Manufacturing and Quality
Richard Rew	Senior Vice President, Legal, General Counsel, and Corporate Secretary
Todd C. Bennet	Senior Vice President, Global Sales and Customer Operations
Steven Back	Vice President, Global Quality Assurance
David Bourne	Vice President, Business Development and Strategic Planning
Charles J. Collins, Ph.D.	Vice President, Research and Development
Thomas J. Copa	Vice President, Licensed Technologies Group
Ronald D. Dunn	Vice President, Global Regulatory and Clinical Affairs
Andrew D. Ewing	Vice President, Customer Experience
Kendel B. Martin, CPA	Vice President, Accounting
Eric S. Shapiro	Vice President, Global Marketing
Reid Sadler	Vice President, Sales and Marketing Americas

### SEC Filings

Filing Date	Form
01/19/18	SC 13G/A
01/08/18	8-K
12/21/17	4
12/18/17	4

Data provided by Nasdaq. Minimum 15 minutes delayed.